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LITHIUM IN PS FCHIATRY i THERAPEUTIC EFFICACY SIDE EFFECTS AND 
PRACTICAL ISSUES* 
S. K. KHANDELWAL' 
Honourable members of the Chair, 
distinguished guests, members of the In-
dian Psychiatric Society, ladies and gen-
tlemen. I feel privileged today in addre-
ssing you on the occasion of delivering of 
prestigious Tilak Venkoba Rao Oration. 
I am thankful to the Indian Psychiatric 
Society for providing me with this oppor-
tunity. I pay humble respect to late 
Tilak Venkoba Rao in whose memory 
Professors Venkoba Rao and Parvathi 
Devi instituted this award honouring both, 
the Society and its young members. Lith-
ium, the subject I have chosen today to 
speak on, has been dear to both, Professor 
Venkoba Rao and Professor Parvathi Devi 
as is evident from large number of rese-
acrch publications on lithium in scientific 
journals by them, I only hope that 1 am 
able to do justice to the topic. I must 
place on record my gratitude to Profe-
ssor N. N. Wig and Professor R. Srini-
vasa Murthy for initiating and encoura-
ging me to do whatever little I have been 
•ible to do on the subject of lithium ion. 
Historical uses of lithium in medi-
cine : 
Before lithium got established as a 
successful drug in psychiatry, it was medi-
cally used in three instances where it not 
only proved to be a failure it created 
a m'strust in the medical world towards 
its use. 
Towards 1850 it was used in the 
treatment of gout and other illnesses 
related to uric acid crystal deposits. 
Later towards 1900, lithium bromide was 
tried as a sedative and an antiepileptic 
drug without much success. In the 1940'i 
lithium was again tried in medicine, not 
as a therapeutic agent, but as a substitute 
to table salt. The indiscriminate use of 
lithium lalts that followed led tomany 
cases of severe poisoning and death in 
some cases bringing disrepute to their 
use. 
Historical perspective use of lithium 
in psychiatry 
It is possible that during the fifth 
century, an African physician, Cealius 
Aurelianus, was recommending the use 
of strong alkaline waters having a high 
concentration of lithium salts for the 
treatment of mania like conditions and it 
continued as effective treatment for many 
centuries (Grantham, 1976) 
In 1949, John F. Cade, an Austra-
lian Psychiatrist reported in the Medical 
Journal of Australia in a new classic arti-
cle the results of the administration of 
lithium salts to patients with psychotic 
excitment (Cade, 1949). The paper did 
not receive the same importance then as 
is granted to it now. This was perhaps 
related to the mistrust and disrepute gene-
rated by many cases of poisoning in car-
diac and hypertensive patients in whom 
lithium salts were used as a substitute for 
table salt. A lukewarm response to 
Cade's article was perhaps also related to 
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a more spectacular psychopharmacological 
revolution which began with chlorpro-
mazine two years later in France (Gran-
tham, 1976). It is also possible that had 
chlorpromazinc been already available, 
there would have been much less pressure 
to seek a ding such as lithium, and its 
discovery would most likely not have been 
made (Maletzky and Blachly, 1971). Cade 
used lithium in ten manic patients, three 
melancholies and six patients of demen-
tia praccox. While manic patients 
showed marked improvement within the 
first two weeks of starting lithium, clini-
cal remission occurring in eight patients, 
the patients of dementia praecox did not 
show any significant improvement. How-
ever, three of them who were usually 
excited, restless and noisy, became quiet 
and amenable for the first time. Patient 
of melancholia did not show any improve-
ment or worsening with lithium. Though 
Cade initially used two salts, citrate and 
carbonate, he increasingly preferred car-
bonate as it seemed to produce less ali-
mentary disturbances. C xde had reported 
a specific anti-manic effect of the lithium 
ion, yet it made little impact on the psy-
chiatric scene during initial years. Cade 
himself observed (Cade, 1977) that since 
the claim was made by a unknown psy-
chiatrist, with no research experience, 
working along in a small chronic mental 
hospital using primitive techniques and 
negligible equipment, it had evoked no 
response in the medical community. The 
pharmaceutical industry was also not in-
terested in a drug which was cheap and 
plentiful and could not he patented (Kiloh 
et al., 1988) It was fortunate that Cade's 
initial report, though published in a jour-
nal with limited circulation outside Aus-
tralia during thosr days, caught the atten-
tion of Mogens Schou of Denmark who 
followed >t up enthusiastically and 
validated and extended the intial obser-
vation<. After SEMI'S paper (Schou et 
al., 1954) a cautious beginning was made 
in Europe. Since the earlier studies repor-
ting effectiveness of lithium in mania were 
uncontrolled, had used loose diagnostic 
criteria, had used other psychotropic 
medications concomitantly, and ratings 
not having been done blindly, lithium 
evoked little interest in America. More-
over the drug companies were slow to 
carry out expensive research because of a 
poor economic outlook in marketing such 
a drug which was a naturally occurring 
element. Nevertheless, prior to the 
acceptance by FDA, many psychiatricts 
used lithium illicitly in an effort to benfit 
their patients and when FDA once with-
held supplies by the manufacturers, some 
smuggling of lithium occurred (Matezky 
and Blachly, 1971). However, once the 
efficacy of lithium was established, FDA 
approved its use in treatment of mania 
in the year 1969 and as a prophylactic 
agent for bipolar affective illness in 1971. 
History of the use of lithium in India 
Inspite of the limitation of lithium in 
having a narrow safety margin and the 
constraints brought about by the nece-
ssity of having regular senim estimations, 
lithium is now extensively used in India 
by all major psychiatric centres. Never-
theless, lithium made its entry in Indian 
psychiatric scene quite slowly and uno-
btrusively. Though many centres must 
have adopted lithium in their clinics in a 
systematic manner at an early date, au-
thor is a are of a certainty of dates in 
two instances. The institute of psychia-
try, Madurai Medical College, Madurai 
started its lithium-clinic in 1974 under 
the dynamic leadership of Professor Ven-
koba Rao and has done commendable 
work on various aspects related to lithium 
use. Professor N. N- Wig at the Postgra-
duate Institute of Medical Education 
and Research, Chandigarh started using 
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ceutical industry was marketing it in 
India. He persuaded the hospital phar-
macy to procure otherwise inexpensive 
lithium powder from market and dispense 
it in capsule form to provide its beneficial 
effects to the patients of recurrent manic 
depressive psychosis. This system conti-
nued till 1973 when lithium was finally 
marketed in capsule form in India. Pro-
fessor R. Srinivasa Murthy formally star-
ted Lithium-clinic at PGIMER, Chandi-
garh in 1975 to organize work related to 
various aspects of lithium. These early 
efforts of Wig and his colleagues led to a 
thesis work in 1970 by a resident to study 
the therapeutic use of lithium in mania 
and its pharmacokinetics. Ten patients 
were given 1800 mg of lithium daily for 4 
days and then 1200mg a day for next 
seventeen days. Serum lithium estima-
tion was done by the method advised by 
Adisen (1967). Patients obtained levels 
varying between. 96-1.49meq/l. None 
of the patients developed any serious side 
effects during three week, though polyu-
ria was noticed (average 3.6 lit./day) 
between 16-17th day which started dec-
reasing thereafter. Clinical ratings sho-
wed definite clinical improvement in 
patients during second week and by third 
week all patients had substantially impro-
ved (Banerjee, 1971). 
Therapeutic and prophylactic role of 
lithium in affective disorders 
Following Cade's discovery of the 
antimanic effect of lithium in manic excit-
ment, a large number of reports appeared 
all over the world confirming Cade's ob-
servations. These reports have been both 
controlled as well as uncontrolled. It is 
not pertinent here to review all such 
reports as comprehensive and analytical 
reviews are already available in many 
books and journals. 
Initial studies even though many of 
them were uncontrolled, yielded important 
information about lithium's efficacy in 
mania, and brought to light various 
factors concerning its administration and 
control. Its strength over neuroleptics 
was established by the fact that it did not 
sedate the patients and produced no 
inconvenient and annoying side effect 
like extrapyramidal symptoms, even 
though it took longer time than neurolep-
tics in producing its antipsychotic effects. 
It also did not result in cognitive 
impairment and other sequalae associated 
with electro-convulsive therapy. 
The first placebo controlled evalua-
tion of lithium in mania was reported by 
Schou et al. in 1954 utilizing a cross-over 
design with alternating two week periodi 
of lithium and placebo. Later similar 
studies were carried out by Maggs (1963) 
and Wharton and Fieve (1966). Several 
investigators undertook studies comparing 
lithium with other medications (Platman, 
1970; Spring et al., 1970; Prien et al., 
1972; Shopsin et al., 1975; Garfinkel et al.. 
1980). Lithium was unequivocally supe-
rior to placebo in controlling manic 
excitment. When compared to drugs 
like chlorpromazine and haloperidol, 
lithium acted more evenly on the entire 
manic picture effecting total normalization 
of emotion and behaviour, prompting, 
Schou (1963) to use the term, normothy-
motic for lithium, a drug with m»od 
normalizing effect. 
The most controversial issue in the 
lithium field has been the prophylactic 
action of lithium in recurrent bipolar 
affective disorders in its ability to atte-
nuate or prevent further manic and 
depressive episodes. When reports of 
such an action first appeared, the notion 
of prophylaxis was a relatively unknown 
one in psychiatry, and many psychiatrists 
found i t difficult to believe in the reality 
of such a phenomenon (Schou, 1976). 
Among the earliest to examine the 
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•ithium were Noack and Trautner (1951) 
and than Schou ct al. (1954). Hartigan 
(1963) and Baastrup (1964) also made 
similar observations independently. These 
and other studies of that time were 
uncontrolled, retrospective, conducted 
over a limited period and had small 
sample selected with an ill defined diag. 
nostic criteria. Yet it seemed remarkable 
that lithium could provide protection 
against both depressive and manic 
episodes. 
After initial uncontrolled and retros-
pective studies, long term prophylactic 
effect of lithium was first systematically 
studied by Baastrup and Schou (1967) and 
later in many largo and multicentred, 
prospective arid double blind trials by An-
gst et al. (1970), Coppen et al. (1971), 
Prien et al. (1974) and Fievc ct al. 1975). 
These studies showed that lithium was an 
effective agent in preventing recurrences. 
There was a drop in the frequency and 
severity of attacks when patients were 
maintained on lithium. 
A number of studies were reported 
from India too. These studies also confir-
med the therapeutic and prophylactic 
effect of lithium in Indian setting 
(Banerjec, 1971; Ghosh et al.. 1977; 
Venkoba Raoct al., 1978; Prakash et al., 
1978; Narayanet al., 1979 and Srinivasa 
Murthy et al., 1981). However, these 
reports have remained uncontrolled and 
retrospective in nature having small 
samples. And, though the use of lithium 
has continued to proliferate, unfortunately 
till date no doub'e blind controlled, 
prospective and multicentred study has 
been carried out in India to document 
usefulness or limitation of lithium in 
Indian condition. Srinivasa Murthy et al. 
(1981) from Chandigarh followed 80 
patients upto five years and found com-
plete prophylaxis in 43% cases and 
partial prophylaxis in 31% cases. Rost 
'26%^ showed marginal or no response 
at all. Other Indian studies also had 
reported similar results and these were 
comparable to Western response rates. 
Lithium use in children with affective 
disorders 
Depression or other affective disorders 
among children had remained a subject 
of considerable controversy for quite some 
time. Research workers expressed the 
opinion that children were incapable of 
experiencing clinically recognisable depre-
ssive state. However, many reports 
appeared which described in detail the 
case-histories of children suffering from 
not only a depressive illness but also from 
bipolar affective disorder (Weinberg and 
Brumback, 1976; Leading article, BMJ, 
1979; Hassanyeh and Davison, 1980; 
Khandelwal ctal., 1981). Later studies 
reported therapeutic and prophylactic 
usefulness of lithium in children (Brum-
back and Weinberg, 1977; Fcinstein and 
Wolpert, 1973; Hassanyeh and Davison, 
1980; Khandelwal et al., 1984a). Results 
of our study on lithium use in seven chil-
dren can be summarized as follows. 
Some children produced diagnostic 
difficulties and only a longitudinal course 
could establish the diagnosis of an affective 
illness. Illness produced considerable 
disorganization of personal and family 
lives of these patients. Family history of 
bipolar affective illness was present in six 
out of seven cases. All the children 
responded well to lithium and tolerated 
the drug remarkably well. In no case, 
were we forced to stop lithium due to its 
side effects. No child experienced exacer-
bation of depressive features while on 
lithium prophylaxis There was no 
impairment of c'ther tubular or glomerular 
functions. We also noticed that compared 
to earlier reports lower serum lithium 
levels were effective for prophylactk 
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Side effects of long term lithium 
treatment. 
The main use of lithium currently is 
prevention of relapses in affective disordc-
ers. This requires treatment to continue 
for several years and this fact must make 
the treating clinician fully aware of the 
possibilities of side effects. 
The clinical implications of side effe-
cts must be appreciated and measures be 
taken to preven t or reduce them as troub-
lesome side effects may compel many pat-
ients to drop out of treatment prematu-
rely. Similarly, an over-reaction to side 
effects, leading to cessation of relapse-pre-
ventive treatment may unnecessarily pro-
duce more harm than the side effects 
themselves 
Over the years a large number of 
reports have enumerated various side eff-
ects of lithium. Lately excellent studies 
have appeared collecting this informa-
tion more systematically and evaluating 
its impact on patients' health and treat-
ment compliance. Many of these side eff-
ects are experienced by the patients or obs-
erved by the clinician while others are det-
ected during physiological or biochemical 
investigations. It is accepted that sympt-
oms of thirst and polyuria caused by impa-
ired renal concentrating ability, hand tre-
mors, weight gain, diarrhoea, hypothy-
roidism, and acne and psoriasis are caused 
by lithium. An much as 80-90% of pati-
ents may experience some side effects and 
many of them more than one side effect 
(Vestergaard ct al., 1979 and 1980 Ven-
koba Rao, 1983) while on lithium. 
Renal function 
Lithium is eliminated almost exclusi-
vely through the kidneys, and the renal 
function is therefore of crucial importance 
for safe lithium treatment. It was known 
that acute intoxication with lithium could 
give rise to renal lesions, Hestbcch et al. 
(1977) almost created a scare by reporting 
chronic interstitial renal lesions in 13 
patients receiving lithium. Since then a 
large number of cross sectional reports 
have appeared in the literature investiga-
ting in detail the alterations in renal 
functions, namely, glomerular filtration 
rate and urine concentrating ability 
(Vestergaard et al., 1979; Schou & Vester-
gaard, 1988; Hullin et al., 1979; Khandel-
wal et ah, 1983 and 1984b,; Hallgren et 
al., 1979; Johnston et al., 1979; Grof et 
al., 1980; Depaulo et al., 1984; Johnson et 
al., 1984; Venkoba Rao, 1979 and 1981; 
Waller and Edwards, 1989). At the 
Department of Psychiatry, PGIMER, 
Ghand'garh author and his colleagues 
systematically studied renal functions of 
patients on long term lithium prophylaxis 
(Khandelwal et al„ 1985). Renal function 
of 40 adult patients (range 20-65 years; 
mean 42.9 years) of manic depressive 
psychosis maintained on mean daily dose 
of 750 mg of lithium for an average of 
4.5 years were studied. Fifteen age and 
sex matched patients receiving psychotro-
pic drugs other than lithium constituted 
the control group. The tests and their 
results are summarized in Table-1. It is 
important to note that except for 24 hour 
urine volume, both the groups had compa-
rable tubular and glomerular functions. 
Similar investigation Was canied out in 
four children (Khandelwal et al., 1984 a,b) 
who had received lithium for 3-5 years. 
Table-2 summarizes the renal functions of 
these children before lithium prophylaxis 
and 3-5 years later-
Since renal functions during lithium 
therapy have generated considerable 
debate, it seems prudent to summarize 
current opinion on this issue from the 
world literature. 
Effect on glomerular filtration rate 
(GFR) 
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TABLE-I Renal function in 40 lithium treated and 15 control patients 
Test 
Serum electrolytes (n»Eqjl)-Na
+ 
K 
ci-
Blood urea (mg/dl) 
Serum creatinine (mg/dl) 
Urine specific gravity 
Urine osmolality (mOsni/1) 
24 hr urinary protein (mg) 
24 hr urinary volume (ml) 
Creatinine clearance (ml/min) 
Lithium group 
134.9±3.9* 
4.4±0.54 
98.5±5-2* 
28±5.7 
1.2±0.22 
1017 .9±3.8 
589.3±81 
60.5±30.2 
I767±541** 
80.9±15 6 
P values, *<0.05; **<0.01; values are mean ± SD 
TABLE-2 Renal function 
Test 
Serum elecrolytes (meq/liter) 
Sodium 
Potasium 
Chlorine 
Bload urea (dl) 
Serum creatinine (dl) 
Urine specfie gravity 
Urine osmolality (mosraol/liter) 
21-hour urinary protein (mg; 
24-hour urine voluir.e (ml) 
Creatinine clear.uicc (ml/miu) 
of four ihildren before lithi 
Before lithium 
prophylaxis 
Mean 
132-7 
4.3 
97.5 
26.0 
12 
1018.7 
Not done 
60.5 
Not done 
Not done 
SD 
2 5 
04 
5.5 
3.7 
0.2 
3.5 
— 
30.2 
— 
— 
urn prophylaxis and 3> 
Control group 
130.3±2-8 
4.2±0-42 
95.5±3.7 
25.4±4-8 
1.1±0.2 
1021±4-2 
611 ±70 
58.4;fc!>0.4 
1546±314 
845±12.4 
•5 yearj later 
Repeat testing 
Mean 
130.* 
4.1 
95.5 
23-4 
1.2 
1022-0 
576 
58.4 
16760 
82.1 
SD 
2.7 
0.5 
3.8 
2.8 
0.1 
3.2 
58 
20.4 
218 
13.6 
estimated by creatinine clearance or cr 
EDTA clearance involving thousands of 
patients has found normal GFR in patients 
maintained on lithium for many years. 
Any lowering of creatinine clearance has 
not been found to correlate with serum 
lithium concentration or duration of 
lithium treatment. Any occasional low 
GFR found could be due to the presence 
of pre-lithium renal disease, or develop-
ment of renal disease independent of 
lithium intoxication. One main source of 
variation in creatinine clearance has been 
incomplete collection of 24 hour urine 
samples which must be assiduously done. 
Effect on tubular function 
Polyuria as a side effect of lithium has 
been known for a long time. This along-
with thirst develops because lithium 
interferes with the action of the antidiure-
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produce a nephrogenic diabetes insipidus 
[ike syndrome. This syndrome is usually 
harmless and completely reversible on 
lithium withdrawal. This side effect seems 
closely correlated with the serum lithium 
levels and it is possible to decrease polyu-
ria by lowering serum lithium levels. 
Giving lithium in a single daily dose has 
also been found effective in decreasing 24 
hour urine volume. 
Renal concentrating ability has also 
been assessed by measuring maximum 
urine osmolality following prolonged 
water deprivation or administering vaso-
pressin or vasopressin analogue DDAVP. 
Gross-sectional as well as longitudinal 
studies have shown impaired urine concen-
trating ability of kidney which is associa-
ted with duration of treatment. However, 
presence of impaired renal concentrating 
ability even for a prolonged duration has 
not produced any serious physical compli-
cations in any patient and is not associated 
with any specific morphological changes 
in the renal tubules. 
^enal morphology 
The initial studies by Hestbech et al. 
(1979) and Hansen et al. (1977) focussed 
attention on chronic morphological chan-
ges in human kidney following prolonged 
lithium treatment. However, patients in 
these studies were selected for renal 
biopsy for having serious lithium pois-
oning or functional impairment. Many 
other studies which have studied morpho-
logical changes in kidney of patients 
receiving lithium, have found them to be 
non-specific which could be found in vari-
ous forms of chronic nephropathy or indu-
ced by other drug- used in treating these 
patients. To conclude question of lithi-
um induced renal side effects, it can be 
safely said that lithium is not nephrotoxic. 
There is no evidence that patients are at 
* risk of progressive renal failure. No 
patient has died from lithium-induced 
renal insufficiency or terminal azotemia. 
Nevertheless annual estimations of serum 
creatinine concentrations should be carried 
out to detect the occasional patient whose 
glomerular fuuetion may be idiosyncra-
tically impaired by lithium. A patient 
may also develop a concurrent renal 
disease that is independent of lithium. 
Also, treatment must be so supervised 
that chances of lithium poisoning are 
reduced to minimal. 
Lithium : Practical issues 
Over the last three decades, scienti-
fic interest in lithium has grown rapidly 
and widely resulting into major publica-
tions about its biology, pharmacology, 
toxicology and clinical uses. The output 
has been so vast that Schou (1982) has 
counted over 600 papers yearly and still 
the plateau is not in sight. Clinical use 
of lithium has been so wide that appro-
ximately two persons per thousand popu-
lation are receiving lithium treatment in 
Canada, United States of America and 
Scandinavian countries (Grof and 
Lane, 1984; Schou, 1989). Despite 
being a popular and an effective treat-
ment, there is a danger of overuse of 
this active element since estimates suggest 
that the prevalence of lithium responsive 
conditions are substantially lower than 
2/1000 in the same population. Hence it 
is mandatory that a clinician remains 
clinically objective in selecting his pati-
ents for lithium use and understands fully 
Well its efficacy, limitations and toxicity 
vis-a-vis the natural history and lithium 
responsiveness of a disease entity. 
Lithium screening and monitoring 
Before lithium got established as a 
therapeutic and prophylactic agent in 
psychiatry, it had already got notoriety 
by its indiscriminate and resultant toxicity 
and fatality. However, over the years 
our knowledge about the side effects of 10;;  S. K. KHA.\D£LW.\I. 
short-term and long-term use has expan-
ded considerably allowing us to screen 
our patients judiciously and monitor 
their treatment rationally. 
Indisputably each patieut must be 
screened carefully once he has been selec-
ted for the possible therapeutic or pro-
phylactic benefit. Opinions vary widely 
in literature regarding an adequate medi-
cal screening procedure for lithium can-
didates. Some workers (Lesar & Tolle-
fson, 1984) have suggested an exhaustive 
scheme to practically evaluate all possible 
physiological functions before a patient is 
put on lithium. Others (Grof, 1933) 
recomme.id an economical approach that 
once a patient is found to have enjoyed 
a past and present good physical health, 
checking serum creatinine and serum 
thyroxine (T4) is adequate. Most others 
(Vastergaardet al., 1982; Gauticr et al., 
1976) have suggested a cautious Dut 
feasible approach. In a developing 
country like ours where lithium use has 
been increasing, prc-lhhium screening 
must be done cautiously and economically 
to aviod expensive investigations which 
may not be available to psychiatrists in 
many centres. 'I able- -3 summarizes the 
most commonly recommended medical 
screening which author and his colleagues 
have found useful for such a purpose. One 
TABLE 3 
Ptf -lithium Midicai Scrrening 
•Medical history and physical examination 
•ftropliasis on ONS, CVS. ren.il and endocrine 
functions 
L&O'tUry Trsls 
—Serum creatinine and electrolytes 
- -Blond Urea 
—24-hour urine volume 
—T4, TSfl 
-Weight 
—E.C.G. (il'abuve 40 years) 
may make modifications in this scheme 
depending upon the general health of the 
patient. For long term monitoring too, 
the therapist can avoid cumbersome and 
expensive investigations if only he is alert 
and knowledgeable about the likely prob-
lems to be encountered in such a patient. 
Regular check on mental status, physical 
health, side effects, weight gain, serum 
lithium levels etc. can ensure a trouble 
free compliance-
Serum lithium levels 
Serum lithium levels though an indi-
rect measure of lithium concentration at 
sites of activity and toxicity, still are clo-
sely related to both therapeutic efficacy 
and side effects. Inadequate levels may 
result in treatment failure, while high con-
centrations result in toxicity. One of the 
primary goals of lithium therapy is to 
maintain the patient's serum lithium 
levels within a narrow therapeutic range. 
Recommended lithium levels for thera-
peutic purpose conventionally range from 
0.8 to 1.2 mEq/1. Levels of 0.6-1.0 mEq/1 
are recommended for maintenance the-
rapy. In the recent past many studies, 
while investigating the effects of lithium 
on kidney highlighted effective prophy-
laxis even when patients were maintained 
on lower serum lithium levels (Hull'n et 
al., 1979; Venkaba Rao et al., 1979;. 
Earlier, Pricm and Caffey (1976) in their 
review had found that a minimum of 
0.8mEq/l was require) to prevent relap-
ses. In a prospective study lasting for more 
than 3 years, Goodnick and Fieve (1985) 
found no difference in interepisodic func-
tioning or side effects in two groups «f 
bipolar patients maintained on low and 
high lithium levels. Since 1979, Schou 
and his colleagues have been maintaining 
their patients on serum level of 0.68mEq/l 
(previously 0.85mEq 1) with no notable 
reduction of prophylactic effcacy, but 
lessening the frequency and intens
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lithium induced side effects. Author and 
his colleagues have also found low serum 
levels to be effective for prophylactic pur-
poses. By maintaining low levels, we 
have also been able to lower the incidence 
and severity of lithium induced side effects 
,K.handelwal etal., 1983, 1984b; Srini-
vasa Murthy et al„ 1981). 
In recent past, the number ofpsy-
chiatric centres using lithium therapy has 
increased significantly, still one limita-
tion in its use seems to be the lack of 
tacility lor serum lithium estimation in 
many places. Kuruvilla (1977) suggested 
that since lithium levels of a single sam-
ple remain stable over a period of time, 
one could send serum by post for analysis 
to a centre offering facility for lithium 
estimation. This was in contrast to ear-
lier understanding that serum estimations 
must be made within six hours of collec-
tion of sample, otherwise it leads to 
deterioration in values (Brown and Legg, 
1970). We too examined this issue. Thirty 
patients receiving lithium were divided 
into two groups. Group I consisted of 
patients whose serum samples were stored 
at i0
oC for subsequent analysis while sera 
of patients ot group II were stored at 
room temperature in tightly covered vials. 
Serum l'thium estimations were done on 
day 1, 3, 5, 7, and to determine whethsr 
storing of sera over a period at different 
temperatures changed the values. It was 
seen that serum lithium values remained 
stable for at least eight days after collec-
tion. Thus psychiatrists having no faci-
lities for serum lithium estimations could 
send patients' sera (by post or otherwise) 
to a centre having a facility (Khandelwal 
etal., 1981 and 1982). 
The necessity of repeated measure-
ment of serum lithium levels has led to 
exploration of alternate methods of moni-
toring lithium therapy. One such alter-
native is estimation of lithium in saliva 
since a positive correlation between lithi-
um contents of saliva and serum has been 
observed Verghese et al. (1977) concluded 
that it was practical 10 measure this ratio 
to monitor maintenance therapy with li-
thium. However, some investigators have 
found the inter and intra-individual 
variations too wide to be of practical value 
in long term lithium therapy (Vlar et al., 
1979; Evrard et al., 1978). We studied the 
usefulness of this ratio in 60 patients on 
lithium therapy (Khare et al., 1983). The 
correlation between serum and salivary 
lithium levels (r=0.73) was found to be 
significant at one percent level The ratio 
ol salivary serum levels to that of serum 
was found to range trom 1.77 to 6.68. The 
ratio of 51% of the samples was between 
3 and 3.99. It is thus important to inden-
tify the subgroup of patients who show 
better correlation ol salivary and serum 
lithium levels and use each individual's 
ratio to monitor only his lithium therapy. 
Lithium : Single or divided dose 
In an attempt to derive maximum 
benefit and least side effects, clinicians 
have been experimenting with a single 
daily dose of lithium following the exam-
ple of neuroleptics and antidepressants. 
The greatest advantage of such a regimen 
would, of course, be improved compliance. 
But then, there may be difficulty in inter-
preting correctly the standardized 12 
hour serum lithium levels. A single loa-
ding dose of lithium would also create 
absortion related difficulities and give 
rise to more gastrointestinal side effects. 
Higher serum peaks resulting from a single 
dose may adeverjely affect the renal tubu-
les. To study some of these issues, we 
studied pharmacokinetics of lithium in six 
normal volunteers following single oral 
administration of conventional (600 mg) 
and later slow release preparation (800 
mg) of lithium carbonate (Khare et al., 
1982). Volunteers tolerated both the 
drugs quite well when given as a single 170  S. K. KHANDELWAL 
dose. Maximum serum concentrations, 
time taken to reach maximum concentra-
tion, volume of distribution and metabo-
lic clearance rates of both the preparations 
were similar. I'andcy et al. (1981) also 
found that it was possible to administer 
conventional lithium preparation in a 
tingle daily dose, The chances of toxic 
li'liium levels were nil and those of sub-
therapeutic levels were minimal in their 
study and they found conventional prepa-
ration to be superior to slow release prepa-
ration. Possibility of renal damage during 
single daily dose regimen has been exami-
ned by many workers (Plenge and Rafael-
son, 1982; Grof, 1984; Perry et al., 1981; 
Muir eta!., 198'J). Consensus which has 
emerged is that patients taking lithium in 
a single daily dose had lower 24 hour 
urine volume and fewer structural changes 
in kidney biopsy than those patients who 
are maintained on multiple doses. 
Why patients discontinue lithium 
It has been seen in many long term 
surveys and naturalistic follow-ups that 
25%-50% of patients receiving long term 
maintenance drug therapy discontinue me-
dication, reduce dose or otherwise fail to 
take the medicatin as prescribed (Prien et 
al., 1984; McCredie et al., 1985; Harrow 
etal, 1990., SrinivasaMurthy ct al., 1981). 
The reasons for discontinuation of lithium 
therapy have been quite varied. One of 
the important reasons to discontinue treat-
ment is side effects which occur in more 
than 40% of cases (Vestergaard et al., 
1988; Vcnkoba Rao etal., 1983). Tre-
mors and memory problems are the most 
common reasons for men to stop lithium, 
while women stop it mainly because of 
polyuria and weight gain. Reduction in 
daily dose and scrum-lithium levels can 
effectively reduce the frequency and seve-
rity of side effects. Another important 
reason for patients to stop lithium is the 
very success of lithium in reducing their 
upswings in mood which they miss (Fols-
tein et al., 1982) while on lithium prophy-
laxis. Patients believe that lithium inter-
feres with their creativity and producti-
vity. In many poorly supervised patients 
discontinuation usally occurs when patient 
is on the verge of hypomania . 
Other reasons contributing to pool' 
compliance and discontinuation are inter-
current physical illnesses, pregnancy, poor 
social support, and a chaotic home envi-
ronment. 
Compliance has been reported to be 
higher in patient with stable marriages 
and in cases where a family member 
assumes a key role in the treatment 
programme. Psychotherapeutic support 
and psychoeducation programmes for 
patient and his family are also helpful in 
increasing patient's adherence to the 
treatment plan. 
Predictors of response to lithium 
Recently, there has been interest in 
subtypes of bipolar affective disorder and 
the concept of bipolar spectrum which 
would include many patients traditionally 
viewed as having recurrent unipolar de-
pression. There are suggestions that bipo-
lar II may have a poorer outcome than 
bipolar I (Joyce and Paykel, 1989). Ra-
pid cyclers, patients with four or more 
recurrences a year (Dunner et al., 1976) 
have been found to do poorly on lithium. 
However, Schou (19d9) suggests that 
many rapid cyclers do respond to lithium 
and one should give them a chance with 
lithium too alongwith exploring the effi-
cacy of levothyroxine, carbamazepine etc. 
A positive family history for bipolar disor-
der appeared to have a favourable response 
in some studies (Mendlewicz et al., 1973; 
Ghosh etal., 1977; Khandelwal etal., 
1984; Maj etal., 1984). But many 
studies recently have not found such 
association (Misra et al., 1977; Page et al., 
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investigators have investigated the course 
of bipolar affective disorder and its lithium 
prophylaxis in relation with expressed 
emotion (EE) of the key family members 
(Miklowitz etal., 1988; Priebe et ah, 
1989). The results suggest that emotio-
nal atmosphere of the family may be an 
important predictor of the course of bipo-
lar disorders and patients living with high 
EE relatives show a significantly poor 
response with prophylactic lithium. 
Age of onset of illness, age at the 
start of lithium, sex of the patient do not 
influence the long term outcome. 
It seems that no consistent results 
have emerged to identify predictors of 
clinical response to lithium. In an indi-
vidual patient, treatment compliance, 
clear affective illness, adequate serum 
levels, good response to lithium in the 
past and well adjusted premorbid persona-
lity may be considered as favourable 
predictors to start lithium prophylaxis. 
Lithium and pregnancy 
Since the thalidomide disaster in 
1961, there has been an increased concern 
regarding the use of psychotropic drugs 
in pregnancy and their resultant effects on 
the growing foetu; since a large number 
of women are exposed to such drugs 
during their fertile period and some of 
them continue to take psychotropic drugs 
during pregnancy. While there is no 
conclusive data to unequivocally docu-
ment teratogenic effects of psychotropic 
drugs, there are reports of higher drug 
consumption by mothers of malformed 
children, of congenital defects in children 
born to mothers taking phenothiazines 
(Van Blerk et al., 1980), and imipramine 
(Idanpaan-Heikkila and Saxen, 1973). 
Lately there have been a number o[ 
report linking the use of lithium in preg-
nancy with any congenital defects and 
neonatal deaths (Schou et al., 1973; 
Weinstein and Goldfield, 1975; Kallen 
andTandberg, 1983; Linden and Rich, 
1983). These reports have obtained data 
from lithium registries and have reported 
a greater than expected frequency to 
congenital cardiac malformations such as 
Ebstein anomaly, co-arctation of aorta, 
patent ductus arteriorus, valvular atresias, 
single umbilical artery etc. Schou et al. 
(1973), Weinstein and Goldfield (1975), 
and Khandelwal et al. (1989) have also 
reported cases of still births. These 
evidence become important in view of the 
fact that a large number of women of 
child bearing age are being given the 
benefit of long term lithium. Clearly, its 
use must be avoided at least during the 
first trimester of pregnancy. The termi 
nation of lithium itself may carry a high 
risk of relapse. The treating clinician 
should take into account the r.sks of alter-
native treatment, frequency and severity 
of the illness and its risk on the foetus and 
weigh these against the risks of lithium. 
Lithium is secreted in breast milk and 
significant concentrations may occur in 
the infant if lithium is recommended 
during post-partum period with continua-
tion of breast feeding. In a follow up 
study of lithium children born without 
malformations, Schou (1976) did not find 
any long term effects of lithium on subse-
quent mental or physical development. 
Conclusion 
Bipolar effective disorders would 
continue to have a major share of our 
work at various levels. Many patients 
suffering from them would require a long 
follow up. Lithium will continue to be 
a major therapeutic intervention in a 
large number of such patients. Inspire 
of being in use for a long time, lithium 
use has remained very casual in India, 
as is perhaps the case with electro-con-
vulsive therapy also. We have been 
using lithium as a routine drug without 
proper patient-selection to obtain frustra-172  S. K. KHANDBLVVAL 
ting results. We must remember that 
lithium is not a panacea. It is not a drug 
meant for all. 11 does produce inconve-
nient side effects and has a potential for 
toxicity too. Yet inspite of all limitations, 
lithium would prove to be a drug of 
choice in carefully selected patients. 
Such careful assessment at the beginning 
of treatment will lessen the dropouts and 
prevent untoward effects during the treat-
ment. Tliis will certainly improve the 
success rate of the therapy. We must 
look afresh at some of the questions like 
responders, daily doses, serum levels, role 
of psychosocial interventions, long term 
outcome and side-effects in context of 
Indian conditions. Organised lithium-
clinics can go a long way in fulfilling some 
of these therapeutic and research aims. 
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